Reset filter
Trefwoorden
D016430 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
    1. 7.1. Anesthesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynaecologie/Ostetrie
    1. 7.6. Interne geneeskunde
      1. Hematologie
      1. Epidemiologie
      1. Cardiologie/Angiologie
      1. Pneumologie
      1. Gastro-enterologie
      1. Nefrologie
      1. Endocrinologie/Metabolisme
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Oogheelkunde
    1. 7.9. Palliatieve zorg
    1. 7.10. Pathologie/Forensische Geneeskunde
    1. 7.11. Kindergeneeskunde
    1. 7.12. Psychiatrie/Psychosomatisch
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Algemene/maag-darm-chirurgie
      1. Neurochirurgie
      1. Plastische chirurgie
      1. Cardiothoracale chirurgie
      1. Traumachirurgie/Orthopedie
      1. Vaatchirurgie
    1. 7.15. Urologie
    1. 7.16. Tandheelkunde/MKG
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

484 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Urinary Bladder, Overactive NCT02385500

- 24-07-19 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Fesoterodine on Urgency Episodes in Parkinson's Disease Population; ODM derived from: https://clinicaltrials.gov/show/NCT02385500

Eligibility DRKS00003516 NCT01374789 Urinary Bladder Cancer - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 39 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01374789

Bladder Cancer NCT01224665 - Pre-Randomization Off-Study Form Bladder Cancer #52060 S1011 NCT01224665

- 24-03-15 - 1 Formulier, 5 Itemgroepen, 24 Data-elementen, 1 Taal
Itemgroepen: Header Module, Treatment Information, Off Treatment Reason, Additional Treatment, Vital Status
S1011 Pre-Randomization Off-Study Form (#52060) Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer NCT01224665 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9399F2B7-7E68-06C0-E040-BB89AD436952

Eligibility Bladder Cancer NCT01954173

- 18-08-19 - 1 Formulier, 2 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Adjuvant Radiation for High Risk Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01954173

Eligibility Bladder Cancer NCT00389155

- 04-10-17 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00389155

Eligibility Bladder Neoplasms NCT00001381

- 10-01-16 - 1 Formulier, 1 Itemgroep, 15 Data-elementen, 1 Taal
Itemgroep: Criteria
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder; ODM derived from: https://clinicaltrials.gov/show/NCT00001381

Eligibility DRKS00004052 NCT00661609 Bladder Cancer - Eligibility Advanced Bladder Cancer NCT00661609

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 8 Data-elementen, 1 Taal
Itemgroepen: Inclusion criteria, Exclusion criteria
Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Eligibility Bladder Dysfunction in MS NCT00913510

- 03-09-18 - 1 Formulier, 2 Itemgroepen, 17 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction; ODM derived from: https://clinicaltrials.gov/show/NCT00913510 Sponsor: Wellspect HealthCare Information provided by (Responsible Party): Wellspect HealthCare Principal Investigator: Clare Fowler, Prof. University College, London

Bladder Cancer CALGB 90104 NCT00014534 - Chemotherapy Dose Form Bladder Cancer (CALGB 90104)

- 25-07-15 - 1 Formulier, 1 Itemgroep, 26 Data-elementen, 1 Taal
Itemgroep: Chemotherapy Dose Form
CALGB: 90104 Chemotherapy Dose Form Combination Chemotherapy in Treating Patients With Bladder Cancer NCT00014534 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1C0B11-7B76-737C-E034-0003BA12F5E7

S0337 Irritative Bladder Symptom Inventory

- 09-06-15 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 1 Taal
Itemgroepen: Header, Bladder Symptoms
S0337 Irritative Bladder Symptom Inventory Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FE24FEF5-9DBA-4A52-E034-0003BA3F9857

Eligibility DRKS00010322 NCT00246974 Bladder Cancer - Eligibility

- 11-12-13 - 1 Formulier, 2 Itemgroepen, 7 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00246974

Follow-Up Form Bladder Cancer (NCT00942331)

- 08-01-15 - 1 Formulier, 8 Itemgroepen, 44 Data-elementen, 1 Taal
Itemgroepen: Header, Vital Status, Treatment Status, Disease Assessment, Measurable Disease Response, Notice of New Primary, Long-Term Toxicity, Non-Protocol Therapy
CALGB 90601: Follow-Up Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6591C082-D8C1-EC1C-E040-BB89AD43479B

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial